Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL

Fateeha Furqan, Timothy S. Fenske, Walter L. Longo, Bryon Johnson, Mehdi Hamadani, Nirav N. Shah

Blood (2022) 140 (Supplement 1): 6407–6408.

https://doi.org/10.1182/blood-2022-170047

Published: 2022

Journal Articles

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Walter L. Longo, Parameswaran Hari, Dina Schneider, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani

Blood (2022) 140 (Supplement 1): 7480–7481.

https://doi.org/10.1182/blood-2022-169119

Published: 2022

Journal Articles

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Murthy, Scott H. Kaufmann, Aniko Szabo, Alexandra M. Harrington, Laura C. Michaelis, Sameem Abedin, Karen Carlson, Lyndsey Runaas, Walter L. Longo, Alexander Hinman, Sonia Maldonado-Schmidt, Althea Thomas, Arielle Baim, Mark R. Litzow, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 2347.

https://doi.org/10.1182/blood-2021-149351

Published: 2021

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Christopher R. D'Angelo, MD, Aric C. Hall, MD, Kyungmann Kim, PhD, Ryan J. Mattison, MD, Walter L. Longo, MD, Peiman Hematti, MD, Natalie Scott Callander, MD, Mark Juckett, MD

Blood (2018) 132 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2018-99-112670

Published: 2018

Journal Articles

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Christopher Peterson, MD, Lakeesha L. Carmichael, MS, KyungMann Kim, PhD, David T. Yang, MD, Anne M. Traynor, MD, Jae E. Werndli, BSc, MSc, Michael Huie, MD, Thomas McFarland, MD, Michael Volk, MD, Jules H. Blank, MD, Natalie S. Callander, MD, Walter L. Longo, MD, Brad S. Kahl, MD

Blood (2016) 128 (22): 149.

https://doi.org/10.1182/blood.V128.22.149.149

Published: 2016

Journal Articles

Utilization of Leftover Autologous Peripheral Blood Stem Cells (PBSCs) in Patients with Multiple Myeloma (MM)

Natalie S Callander, MD, Walter L. Longo, MD, Mark B. Juckett, MD, Vaishalee P. Kenkre, MD, Peiman Hematti, MD, Janelle McMannes, Rebecca K Evans, Linda A Eckstein, MSN,NP, Blythe Gage, NP

Blood (2014) 124 (21): 2654.

https://doi.org/10.1182/blood.V124.21.2654.2654

Published: 2014

Journal Articles

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

Ginna G. Laport, MD, Juan Wu, MS, Brent R. Logan, PhD, Veronika Bachanova, MD, Chitra M. Hosing, Timothy S. Fenske, MD, Walter L. Longo, MD, Steven M. Devine, MD, Auayporn P. Nademanee, MDBS, Iris Gersten, MS, Mary M. Horowitz, MD MS, Hillard M. Lazarus, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 682.

https://doi.org/10.1182/blood.V124.21.682.682

Published: 2014

Journal Articles

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Lyndsey Runaas, MD, Walter L. Longo, MD, Mark Juckett, MD, Wayne Borcherding, BS, Peiman Hematti, MD, Rachel J Cook, MD, MS

Blood (2013) 122 (21): 5490.

https://doi.org/10.1182/blood.V122.21.5490.5490

Published: 2013

Journal Articles

Thalidomide (HAL) Maintenance Following High-Dose Melphalan with Autologous Stem Cell Transplant (ASCT) for Myeloma.

Julie E. Chang, MD, Mark B. Juckett, MD, Brad S. Kahl, MD, Teri L. Mitchell, Ronald E. Gangnon, PhD, Natalie S. Callander, MD, Walter L. Longo, MD

Blood (2006) 108 (11): 5455.

https://doi.org/10.1182/blood.V108.11.5455.5455

Published: 2006

Journal Articles

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Brad S. Kahl, MD, James McGovern, MD, Jules Blank, MD, Anthony Jaslowski, MD, Gerald Bayer, MD, Wayne A. Bottner, MD, Hamied Rezazadeh, MD, Thomas McFarland, MD, David Hei, MD, Jamie Smith, Emily A. Stevens, Jens C. Eickhoff, Ph.D., Walter L. Longo, MD

Blood (2004) 104 (11): 1388.

https://doi.org/10.1182/blood.V104.11.1388.1388

Published: 2004

Journal Articles

Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

Blood (1998) 92 (7): 2303–2314.

https://doi.org/10.1182/blood.V92.7.2303

Published: 1998

NARROW

MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Utilization of Leftover Autologous Peripheral Blood Stem Cells (PBSCs) in Patients with Multiple Myeloma (MM)

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Thalidomide (HAL) Maintenance Following High-Dose Melphalan with Autologous Stem Cell Transplant (ASCT) for Myeloma.

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only